Evommune Inc

EVMN

Valor de mercado US$ 188 mi

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD) during a late-breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna,.

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the upcoming European Academy of Dermatology & Venereology (EADV) Congress, taking place in Vienna, Au.

Evommune stock dropped Wednesday after its experimental eczema treatment flopped in midstage testing. The bearish news followed another miss for the drug in treating hives.

On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis.

Evommune said on Tuesday it will not advance its experimental skin disease drug ​after it failed to meet the main ‌goal in a mid-stage trial, sending its shares down 24% in aftermarket trading.

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist, EVO756, in adults with moderate-to-severe.

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. "There are still no first-line oral options for patients suffering with AD that combine lesion control, itch relief and tolerability. That gap is where we.

PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine. "Initiating this migraine trial is an exciting mileston.

Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session. NEW YORK, July 7, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shareholders lost approximately 38% of their investment value on June 29, 2026, when the Company disclosed that its lead drug candidate EVO756 failed to meet the primary endpoint -- mean change in UAS7 at 12 weeks -- in its Phase 2b trial for moderate-to-severe chronic spontaneous urticaria (CSU).

Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.